相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G. Fakih et al.
LANCET ONCOLOGY (2022)
Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells
Xing-Duo Dong et al.
FRONTIERS IN PHARMACOLOGY (2022)
MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer's Disease
Yoon Sun Chun et al.
MOLECULAR PSYCHIATRY (2022)
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
Chenmala Karthika et al.
LIFE-BASEL (2022)
Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update
Kritika Engle et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Jill Hallin et al.
NATURE MEDICINE (2022)
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
Katelyn F. Handley et al.
MOLECULAR CANCER THERAPEUTICS (2021)
KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
J. Weiss et al.
ANNALS OF ONCOLOGY (2021)
CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
M. Fakih et al.
ANNALS OF ONCOLOGY (2021)
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey Shapiro et al.
INVESTIGATIONAL NEW DRUGS (2020)
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K. Ramanathan et al.
TARGETED ONCOLOGY (2020)
Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion
Rui Wang et al.
MOLECULAR CANCER RESEARCH (2019)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers (vol 25, pg 620, 2019)
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Chih-Shia Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA
Kiran Kundu et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Improved chemotherapy modeling with RAG-based immune deficient mice
Mark Wunderlich et al.
PLOS ONE (2019)
3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs
Ana S. Nunes et al.
BIOTECHNOLOGY AND BIOENGINEERING (2019)
Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy
Susmita Ghosh et al.
FRONTIERS IN ONCOLOGY (2019)
Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning
Sigrid A. Langhans
FRONTIERS IN PHARMACOLOGY (2018)
Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
M. Pek et al.
ONCOGENE (2017)
BRCA1 expression serves a role in vincristine resistance in colon cancer cells
Zhongjie Xu et al.
ONCOLOGY LETTERS (2017)
Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion
Rajat Bhattacharya et al.
BRITISH JOURNAL OF CANCER (2017)
Not only P-glycoprotein: Amplification of the &ITABCB1&IT-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins
Ilaria Genovese et al.
DRUG RESISTANCE UPDATES (2017)
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Elizabeth K. Ziemke et al.
CLINICAL CANCER RESEARCH (2016)
Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells
Rajat Bhattacharya et al.
CANCER RESEARCH (2016)
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
J. E. Grilley-Olson et al.
INVESTIGATIONAL NEW DRUGS (2016)
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Tao Hu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
Michael S. Lee et al.
ONCOTARGET (2016)
3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained
Michele Zanoni et al.
SCIENTIFIC REPORTS (2016)
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
Khanh Do et al.
INVESTIGATIONAL NEW DRUGS (2015)
Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter
Jian-Ge Qiu et al.
ONCOTARGET (2015)
Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
Shunsuke Okumura et al.
CLINICAL CANCER RESEARCH (2014)
A New Bliss Independence Model to Analyze Drug Combination Data
Wei Zhao et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman et al.
AGING-US (2011)
Activation of AMP-Activated Protein Kinase is Involved in Vincristine-Induced Cell Apoptosis in B16 Melanoma Cell
Min-Bin Chen et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Combined Inhibition of MEK and mTOR Signaling Inhibits Initiation and Progression of Colorectal Cancer
Yan-Jie Zhang et al.
CANCER INVESTIGATION (2009)
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Olga K. Mirzoeva et al.
CANCER RESEARCH (2009)
分享论文
